Tectonic Therapeutic (TECX)
NASDAQ:TECX
TECX Stock Chart & Stats
$30.72
-$0.66(-1.42%)
At close: 4:00 PM EST
$30.72
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$14.39 - $36.03
Previous CloseN/A
Volume30.18K
Average Volume (3M)275.80K
Market Cap
$576.82M
Enterprise Value$324.30M
Total Cash (Recent Filing)$253.80M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 07, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding18,776,627
10 Day Avg. Volume161,223
30 Day Avg. Volume275,802
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.54
Forecast
1Y Price Target
$82.67Price Target Upside169.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Progress And DesignAPEX Phase 2 is actively dosing at multiple clinical sites with enrollment focused on patients with combined pre/post-capillary pulmonary hypertension and pulmonary vascular resistance as the primary endpoint to increase the chance of detecting a meaningful treatment effect.
Pipeline Diversification And MechanismA first-in-class APJ antagonist program and a long-acting subcutaneous TX2100 alongside TX45, which has a distinct pharmacokinetic profile, broaden the pipeline and could expand the company's addressable market if early studies show activity.
Safety And ToxicologyNonhuman primate toxicology studies reported no key safety signals and independent safety reviews found no concerns, supporting continued clinical development of the lead program.
Bears Say
Financial RunwayHigh cash burn and a limited cash runway raise the risk of future financing needs that could dilute existing holders and pressure the stock.
Market Volatility And Short InterestElevated short interest combined with a modest cash runway increases the likelihood of sharp stock volatility and could complicate access to financing.
Mechanism And Competitor RiskFailure of a similar relaxin Fc-fusion in Phase 2 for lack of efficacy heightens investor skepticism toward the relaxin mechanism and could weigh on valuation and investor confidence.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $14.38 and its highest was $36.03 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Tectonic Therapeutic’s market cap is $576.82M.
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Feb 26, 2026. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.088 by $0.058.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -1.16.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 18,776,627 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.088. Following the earnings report the stock price went down -2.006%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.67 (169.11% Upside)
$82.67 (169.11% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 163.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $182.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.17%
12-Months-Change
Fundamentals
Return on Equity
-26.87%
Trailing 12-Months
Asset Growth
70.72%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$82.67
▲(169.11% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
39.32% Insiders
13.72% Mutual Funds
30.28% Other Institutional Investors
10.81% Public Companies and Individual Investors
Options Prices
Currently, No data available
---